Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®))

Tyrosine kinase inhibitors are currently applied in the treatment of non-small cell lung cancer with overexpressed epidermal growth factor receptor (EGFR). Acneiform rash is the earliest and most characteristic side effect of EGFR inhibition. The incidence may be as high as 50-100% of cases. We repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Owczarczyk-Saczonek, Agnieszka, Witmanowski, Henryk, Placek, Waldemar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834717/
https://www.ncbi.nlm.nih.gov/pubmed/24278074
http://dx.doi.org/10.5114/pdia.2013.35624
Descripción
Sumario:Tyrosine kinase inhibitors are currently applied in the treatment of non-small cell lung cancer with overexpressed epidermal growth factor receptor (EGFR). Acneiform rash is the earliest and most characteristic side effect of EGFR inhibition. The incidence may be as high as 50-100% of cases. We report a case of a 47-year-old patient who developed acneiform rash after 1.5 weeks of treatment with erlotinib.

Ejemplares similares